Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo

Achim Aigner

Abstract Within the recent years, RNA interference (RNAi) has become an almost-standard method for in vitro knockdown of any target gene of interest. Now, one major focus is to further explore its potential in vivo, including the development of novel therapeutic strategies. From the mechanism, it becomes clear that small interfering RNAs (siRNAs) play a pivotal role in triggering RNAi. Thus, the efficient delivery of target gene-specific siRNAs is one major challenge in the establishment of therapeutic RNAi. Numerous studies, based on different modes of administration and various siRNA formulations and/or modifications, have already accumulated promising results. This applies to various animal models covering viral infections, cancer and multiple other diseases. Continuing efforts will lead to the development of efficient and “double-specific” drugs, comprising of siRNAs with high target gene specificity and of nanoparticles enhancing siRNA delivery and target organ specificity.

Keywords RNA interference · RNAi · siRNA · Gene-targeting · Gene knockdown · Nonviral siRNA delivery · Nanoplexes

Introduction

After antisense technologies and ribozymes, in the late 1990s a novel mechanism for gene-targeting was discovered: RNA interference (RNAi). It soon became clear that RNAi represents a particularly efficient and—at least in vitro—easy-to-use method for the knockdown of the expression of a selected target gene. Consequently, RNAi is now a well-established method for high-throughput analyses as well as for functional studies in vitro, including mammalian cells.

Many pathological conditions rely on the aberrant expression of endogenous normal or mutant genes causing, e.g., alterations in signal transduction pathways, cellular proliferation, apoptosis, or resistance toward external factors. Additionally, the infection of an organism can lead to the introduction and expression of foreign genes. While the inhibition of the activity of (aberrant) gene products, e.g., through small molecule inhibitors or inhibitory antibodies is one major focus in therapy, much attention has now shifted to an earlier step, i.e., the initial knockdown of the specific gene of interest through RNAi. However, for the in vivo application of RNAi in mammals as a therapeutic approach for reversing a pathological condition as well as for the study of particular gene functions, sophisticated strategies for the induction of RNAi are needed.

Mechanism and induction of RNAi

RNAi is a naturally occurring, sequence-specific mechanism for gene silencing. Its discovery in the nematode C. elegans (Fire et al. 1998) was awarded the 2006 Nobel prize for physiology or medicine. However, soon it became obvious that RNAi, although somewhat more complicated, also exists in higher organisms including mammals. RNAi relies on an intracellular multistep process, which can roughly be divided into the initiation phase (see below) and the subsequent effector phase. In the effector phase (Fig. 1, left), which represents the actual RNAi mechanism, small, 21–23 bp double stranded RNA molecules (small interfering RNAs, siRNAs), are incorporated into the RNA-
induced silencing complex (RISC; Hammond et al. 2000). Upon adenosine triphosphate (ATP)-dependent unwinding of the double-stranded siRNA molecule through an RNA helicase activity into a single-stranded, so-called guidance RNA (Nykanen et al. 2001), the now activated RISC (RISC*) binds to its target mRNA molecule (Martinez et al. 2002; Nykanen et al. 2001). This process is mediated through the sequence-specific hybridization of the guidance RNA to the mRNA target site and brings RISC into close proximity to its target mRNA molecule, which is then cleaved by the RISC nuclease Argonaute 2 (Ago 2) and rapidly degraded due to its now unprotected ends (Liu et al. 2004; Rand et al. 2004; Rivas et al. 2005). Since RISC is recovered for subsequent rounds, this represents a catalytic process leading to the selective reduction in specific mRNA molecules and thus resulting in decreased expression of the targeted gene. The mechanism also demonstrates the pivotal role of siRNA molecules in initiating RNAi and established the delivery of siRNA molecules as sufficient for RNAi induction (Elbashir et al. 2001a, b).

Induction of RNAi: the initiation phase

In a natural, experimental or therapeutical setting, siRNAs can be directly or as precursor molecules introduced into a target cell through different strategies (Fig. 1, upper part). This includes viral or nonviral delivery of DNAs, which are transcribed into long, double-stranded RNA molecules. In the so-called initiation phase, these dsRNAs are cleaved into siRNAs by the multiprotein complex “Dicer”, which contains an N-terminal helicase domain, an RNA-binding so-called Piwi/Argonaute/Zwille (PAZ) domain, two RNase III domains and a double-stranded RNA binding domain (Bernstein et al. 2001; Collins and Cheng 2005). Commercially available systems explore this mechanism by providing DNA vector constructs coding for short hairpin RNAs (shRNAs): The double-stranded region of the shRNA is formed through hairpin formation and intramolecular hybridization and is recognized by Dicer, leading to the formation of siRNAs homologous to the target gene of interest. Alternatively, shRNA molecules can be directly introduced into the cell. However, one major disadvantage of long double-stranded RNA molecules, either directly introduced or intracellularly transcribed, is the induction of a cellular immune response through activation of the interferon system. The direct delivery of siRNA molecules into the target cell largely avoids this problem, although some interferon-stimulating sequences are known as well. Furthermore, it does not require the action of Dicer (Bridge et al. 2003; Hornung et al. 2005; Sledz et al. 2003).

Systematic studies on targeting efficacies have shown that optimal siRNAs can be deduced according to certain selection rules. This includes an optimal length of 19–25 bp and a guanine–cytosine content between 30 and 52%, symmetric two nucleotide 3′ overhangs as well as specific nucleotides at certain positions (see, e.g., Dykxhoorn and Lieberman 2006 for review). Based on these already established criteria, several computer-based algorithms allow the identification of optimal siRNA sequences for any given gene of interest. One example is the siRNA
Design Software (SDS) by the University of Hong Kong which combines algorithms from different companies and is accessible through the internet (http://i.cs.hku.hk/~sirna/software/sirna.php). Nevertheless, any presumably optimal siRNA still requires extensive testing. This refers to a high targeting efficacy, which is, among others, also determined by variations in the accessibility of the target mRNA at different positions, as well as to the absence of any unwanted side effects. In fact, nonspecific silencing of genes due to only partial sequence homology has been described (Jackson et al. 2003). Furthermore, in vivo some siRNA sequences, as well as longer dsRNA molecules, have been shown to activate the innate immune system leading to nonspecific effects due to the stimulation of inflammatory responses (Heil et al. 2004; Judge et al. 2005; Sioud 2005; Sledz et al. 2003). This phenomenon seems to depend on the presence of GU-rich sequences as well as on the formulation and amount of siRNAs (Heidel et al. 2004; Ma et al. 2005; Sioud and Sorensen 2003), and these aspects need to be considered for any therapeutic siRNA application in vivo.

Use of siRNA molecules in vivo

Since the discovery of the pivotal role of siRNAs for inducing RNAi (Elbashir et al. 2001a, b), the direct application of siRNA molecules has been explored in vitro and in vivo. In vitro, several transfection reagents allow the delivery of siRNAs in mammalian cells in the presence or absence of serum. The in vivo application of siRNAs, however, requires the development of more sophisticated formulations and/or the identification of optimal modes of administration (see below).

Several proof-of-principle studies have shown the delivery of fluorophor-labeled siRNA molecules into various organs (see, e.g., Bradley et al. 2005a, b; Pirollo et al. 2006; Sioud and Sorensen 2003). Beyond that, the specific in vivo knockdown of artificially introduced reporter genes like GFP or luciferase, or various endogenous target genes, has been described. The target organ was often the liver, but gene targeting in other organs, in other parts of the body, or in tumor xenografts has been reported as well (Table 1). Taken together, these studies provide valuable insights into the delivery and efficacy of siRNAs for the induction of RNAi.

Therapeutic siRNA molecules

Beyond the detection of the downregulation of an endogenous target gene, the siRNA-mediated RNAi for therapeutic purposes has been explored. Target organs include liver, kidney, lung, eye, ear, heart, pancreas, tumors, blood, as well as the central nervous system, and the peritoneum (see Table 1 for an overview), using locally or systemically administered siRNAs in various formulations.

Cancer

A large body of studies refers to the treatment of cancer with the primary goals being the inhibition of tumor growth. Target molecules usually represent genes that have been shown previously to be relevant or rate-limiting for tumor growth, including growth factors and receptors as well as antiapoptotic or downstream signal transduction proteins in tumor cells. Typically, these studies involve subcutaneous or orthotopic xenografts of different tumor entities in mice, and employ various strategies for local or systemic administration of a wide variety of siRNA formulations (see below). In some cases, the antiangiogenic effect after siRNA delivery to tumor endothelial cells, rather than an inhibitory effect on tumor cells, was explored (Santel et al. 2006a, b), or simultaneous targeting of tumor growth and tumor angiogenesis both contributed to the antitumorigenic effects observed (Grzelinski et al. 2006). Additionally, in some studies the blockage of cancer metastasis, e.g., to the lung, liver or bone has been achieved. Taking into consideration that a large number of cancer patients die from metastases rather than the primary tumor, this represents another very relevant approach in cancer therapy.

Antiviral treatment

Several studies focus on viral gene products, taking into consideration that options for protection or therapy through current antiviral drugs or vaccination strategies are rather limited. Thus, novel RNAi-based approaches to battle viral infections rely on the specific siRNA-mediated knockdown of virus-specific genes. Animal models infected with various viruses including hepatitis virus, influenza virus, respiratory syncytial virus (RSV), SARS corona viruses, or ebola virus have been employed, and primary goals were the reduction in virus titers and protective effects including, when lethal doses were applied, prolonged survival rates upon specific siRNA treatment.

Other targets

Beyond studies related to cancer or viral infection, several target molecules with proven relevance in other pathologies have been selected. Examples include Fas in hepatitis, vascular endothelial growth factor (VEGF) in macular degeneration due to extensive ocular neovascularization or tumor necrosis factor alpha (TNF-α) in arthritis, and these
studies aim at the establishment of novel, improved therapeutic avenues through siRNA-mediated gene silencing. As it can be seen from Table 1, some target genes are relevant in more than one pathology (e.g., Fas in fulminant hepatitis, in renal ischemia-reperfusion injury or in hemorrhagic shock and sepsis in the lung; VEGF in age-related macular degeneration or in tumor growth/tumor angiogenesis; caspase-8 in liver failure or in sepsis), and thus, specific siRNAs may represent drugs applicable for the treatment of different diseases. Some studies also compare siRNA-based therapeutic strategies with already established drugs and discuss decreased side effects and/or higher specificity, or additive effects upon combination of both.

Other papers rather aim at the further elucidation of physiological processes through in vivo knockdown of a certain target gene. Examples include OATC3 in blood-brain barrier transport, V2R in water and sodium homeostasis, or HO-1 in lung ischemia-reperfusion injury (Table 1).

Clinical trials

It should be noted that, although the therapeutic potential of siRNAs has only been explored in the recent years, first siRNA-based drugs are already in clinical trials. This includes ALN-RSV01 (Alnylam Pharmaceuticals) for targeting the human RSV after viral infection, which is the first example of an antivirus siRNA-based therapeutic in a phase I clinical study. Other companies aiming at the development of RNAi therapeutics for viral diseases include Nastech/Galenea, which are expected to start clinical trials in 2007. Benitec, in collaboration with City of Hope in Duarte, California, has developed a multi-RNA therapeutic for treatment of AIDS lymphoma. Furthermore, age-related macular degeneration (AMD) was treated with Sirna-027 (Sima Therapeutics) targeting the VEGF receptor VEGFR1 (Shen et al. 2006), and resulted in stabilization or even improvement of visual acuity (Whelan 2005). A 24-month phase II study to evaluate multiple doses of Sirna-027 (also termed AGN211745) in the treatment of subfoveal choroidal neovascularization associated with AMD is currently recruiting patients. Targeting the ligand (VEGF) rather than its receptor, Cand5 (Acuity Pharmaceuticals) has been employed for treatment of the same disease, and in the so-called C.A.R.E.™ trial showed no adverse effects related to the drug. Cand5, which is now named Bevasiranib, was the first siRNA to enter both phase I and II clinical trials. Recently, SR Pharma plc announced the start of a phase I clinical trial with RTP-801i, an siRNA therapeutic licensed from its subsidiary Atugen AG that targets a gene product involved in the progression of AMD. The same company has most recently announced that the FDA has approved an investigational new drug (IND) application for a second siRNA therapeutic, AKII-5 being developed for the treatment of acute kidney injury. AKII-5 is expected to reduce the frequency of postsurgery acute kidney injury in high-risk patients undergoing major cardiovascular surgery. Finally, after successful completion of experiments demonstrating its therapeutic efficacy in animal models of pancreatic cancer, Atu027 is scheduled to enter human clinical trials in 2007. In addition, several other pharmaceutical or biotechnology companies are pursuing collaborative or internal projects for the development of drugs based on RNAi (see, e.g., Behlke 2006 for review).

**Strategies for in vivo siRNA delivery**

Advantages of the direct application of siRNAs, rather than DNA-based constructs coding for long dsRNA, include the relatively easy chemical synthesis of small RNA molecules, the lower probability of nonspecific side effects (see above) and the safety due to the fact that siRNA delivery is based on nonviral transfer strategies and siRNAs cannot integrate into the genome. On the other hand, successful siRNA-based gene targeting relies on several preconditions: protection of the rather unstable siRNA molecules from nucleolytic degradation by serum nucleases, efficient cellular uptake and subsequent intracellular release into the cytoplasm, as well as the absence of intracellular immune responses, in vivo toxicity or rapid elimination in liver or kidney.

Strategies for the in vivo application of siRNA molecules include local as well as systemic modes of administration as detailed in Table 2. However, many studies rely on the use of relatively high amounts of siRNAs. Bearing in mind that intracellular immune responses have been shown to be concentration-dependent, this may increase the risk of nonspecific effects in addition to other side effects and cost considerations. When siRNAs are administered locally, lower doses are sufficient since nonspecific delivery to other organs as well as renal or hepatic elimination are reduced. This approach, however, is invasive and limited to tissues that are sufficiently accessible. With regard to systemic application, several studies rely on the hydrodynamic transfection of siRNAs, i.e., the rapid (∼20 s) high-pressure injection of large volumes (up to 2 ml) of siRNA-containing solution. Hydrodynamic injection has led to the efficient induction of RNAi in liver as well as in kidney, lung, pancreas, and spleen and is probably due to the transient enhancement of membrane-permeability. However, in animals, side effects have been observed (Zhang et al. 2004a, b), and in man, this method is not applicable at all.

Many groups have employed different approaches for the formulation of siRNAs in carrier systems (Table 3), which deliver their siRNA “payload” into the target tissue.
Table 1 Overview on studies employing siRNA-mediated gene-targeting in vivo

| Location/target organ/target mechanism/aim | Targeted gene product | Reference |
|-------------------------------------------|------------------------|-----------|
| Proof-of-principle                         |                        |           |
| Reporter genes                            |                        |           |
| Peritoneal cavity                          | GFP                    | de Jonge et al. 2005 |
| Developing vascular network of chicken embryo | GFP                   | Bollerot et al. 2006 |
| S.c. HeLa xenograft                        | GFP                    | Bertrand et al. 2002 |
| Liver                                     | GFP                    | Lewis et al. 2002   |
| Muscle                                    | GFP                    | Golzio et al. 2005  |
| Bronchiole epithelial cells                | EGFP                   | Howard et al. 2006  |
| Liver and limb grafts                      | DsRed2, GFP            | Sato et al. 2005    |
| Liver                                     | Luciferase             | McCaffrey et al. 2002 |
| Brain                                     | Luciferase             | Hassani et al. 2005 |
| S.c. melanoma xenografts/hepatic metastases | Luciferase            | Takahashi et al. 2005 |
| Endogenous genes                           |                        |           |
| Liver                                     | Fas                    | Heidel et al. 2004  |
| Pancreas                                  | Ins2                   | Bradley et al. 2005a, b |
| Liver                                     | mdr1a/1b               | Matsui et al. 2005  |
| Liver                                     | PLK-1                  | Zimmermann et al. 2006 |
| Hypothalamus                              | TRβ1 + 2               | Guissouma et al. 2006 |
| Vasculature                               | CD31, Tie2             | Santel et al. 2006a, b |
| Cancer                                    |                        |           |
| Tumor growth inhibition                    |                        |           |
| Pancreatic adenocarcinoma xenografts       | CEACAM6                | Duxbury et al. 2004 |
| Fibrosarcoma xenografts                    | VEGF                   | Filleur et al. 2003 |
| S.c. pancreatic carcinoma xenografts       | bcl-2                  | Ocker et al. 2005  |
| Bladder cancer xenografts                  | Survivin               | Hou et al. 2006    |
| Peritoneal cavity                          | β-catenin              | Verma et al. 2003  |
| Bladder cancer                            | PLK-1                  | Nogawa et al. 2005 |
| S.c. prostate carcinoma xenografts         | bcl-2                  | Yano et al. 2004   |
| Prostate cancer xenografts                 | Raf-1                  | Pal et al. 2005    |
| S.c. breast cancer xenografts              | c-raf                  | Chien et al. 2005  |
| Ovarian cancer xenografts                  | FAK                    | Halder et al. 2006 |
| Liver tumor xenografts                     | PTEN, CD31             | Santel et al. 2006a, b |
| Breast tumor xenografts                    | Raf-1                  | Leng and Mixson 2005 |
| S.c. prostate carcinoma xenografts         | VEGF                   | Takei et al. 2004  |
| Orthotopic germ cell tumor xenografts (testes) | HST-1/FGF-4           | Minakuchi et al. 2004 |
| S.c. melanoma xenografts                   | c-myc, MDM2, VEGF     | Song et al. 2005   |
| S.c. ovarian carcinoma xenografts          | HER-2                  | Urban-Klein et al. 2005 |
| S.c. N2A neuroblastoma xenografts          | VEGF R2                | Schiffelers et al. 2004 |
| S.c. breast cancer xenografts              | RhoA                   | Pille et al. 2006  |
| S.c. pancreatic carcinoma xenografts       | Mutant K-ras           | Zhu et al. 2006    |
| Cervical cancer xenografts                 | HPV E6 + E7            | Fuji et al. 2006   |
| Melanoma xenografts                        | SOCS1                  | Yang et al. 2006   |
| Blockage of cancer metastasis              |                        |           |
| Metastatic breast cancer cells             | CXCR4                  | Liang et al. 2005  |
| Lung metastasis                           | Tissue factor          | Amarzguioui et al. 2006 |
| Liver metastasis                          | bcl-2                  | Yano et al. 2004   |
| Bone-metastatic prostate cancer            | EZH2                   | Takeshita et al. 2005 |
| Others                                    |                        |           |
| Cancer vaccine potency (antigen-presenting cells) |                | Bak, Bax | Kim et al. 2005 |
| Breast cancer xenografts, induction of tumor apoptosis | | HER-2 | Hogrefe et al. 2006 |
| S.c. HeLa xenografts, enhancement of cisplatin effect | | Rad51 | Ito et al. 2005 |
| Vein grafts, attenuation of intimal hyperplasia | | Midkine | Banno et al. 2006 |
| Viral infections                           |                        |           |
| Inhibition of HBV replication              | HBsAg                  | Giladi et al. 2003; Klein et al. 2003 |
| Coxackie viral cytopathogenicity           | CVB 2A                 | Merle et al. 2005 |
| Influenza virus infections                 | Nucleoprotein, acidic polymerase | Tompkins et al. 2004 |
and target cell, some of them already being known as DNA delivery techniques in gene therapy or antisense targeting.

**Liposomal formulations**

Various liposomes/cationic lipids can be considered as examples of nonviral envelopes that protect siRNAs, thus increasing serum stability, reducing renal excretion and mediating siRNA uptake into the cells through endocytosis. The comparison of neutral versus cationic liposomes also reveals that the biodistribution as well as the uptake into macrophage seems to be dependent on their charge (Landen et al. 2005; Miller et al. 1998), thus emphasizing the need for the further development and analysis of different liposomal particles. SNALPs (stable nucleic acid lipid particles) have been used for siRNA-mediated targeting of an Ebola-virus-specific gene (Geisbert et al. 2006) or ApoB. This is also the first study that describes the systemic efficacy of formulated siRNAs in a nonrodent species (Zimmermann et al. 2006).

**Table 1 (continued)**

| Location/target organ/target mechanism/aim | Targeted gene product | Reference |
|-------------------------------------------|-----------------------|-----------|
| Respiratory viral diseases                | RSV-P, PIV-P          | Bitko et al. 2005 |
| Reduction of plasma viremia levels        | ZEBOV L               | Geisbert et al. 2006 |
| Reduced serum HBV DNA                    | HBV, HBsAg            | Morisse et al. 2005a, b |
| Influenza virus infections               | Influenza virus genes | Ge et al. 2004 |
| Respiratory viral diseases               | RSV-P, PIV-P          | Bitko et al. 2005 |
| **Organ-specific effects**               |                       |           |
| Liver                                     |                       |           |
| Fas-mediated apoptosis/acute liver failure| Caspase-8             | Zender et al. 2003 |
| Fulminant hepatitis                       | Fas                   | Song et al. 2003 |
| Kidney                                    |                       |           |
| Renal ischemia-reperfusion injury        | Fas                   | Hamar 2004 no. 829 |
| Glomerulonephritis                       | TGF-β1                | Takabatake, 2005 no. 8273 |
| Lung                                      |                       |           |
| Hemorrhagic shock and sepsis (lung)      | Fas                   | Perl et al. 2005 |
| Acute lung injury                         | KC, MIP-2             | Lomas-Neira et al. 2005 |
| Functional analysis in lung ischemia-reperfusion injury | HO-1 | Zhang et al. 2004a, b |
| Increase in lung vascular permeability   | Caveolin-1            | Miyawaki-Shimizu et al. 2005 |
| Decreased formation of obstructive bronchiolitis | MIF | Fukuyama et al. 2005 |
| CNS                                       |                       |           |
| Reduction of brain-to-blood transport    | Organic anion transporter 3 | Hino et al. 2006 |
| Chronic neuropathic pain/decreased hyperanalgesia | Pain-related cation channel P2X3 | Dorn et al. 2004 |
| Temporal hyperlocomotor response         | Dopamine transporter  | Thakker et al. 2004 |
| Antidepressant-related behavioural response | Serotonin transporter | Thakker et al. 2005 |
| Antinociception                          | Delta opioid receptor DLT | Luo et al. 2005 |
| Modulation of pain                       | NMDA receptor NR2B    | Tan et al. 2005 |
| Eye                                       |                       |           |
| Antiapoptosis in retinal ganglion cells  | c-Jun, Bax, Apaf-1    | Lingor et al. 2005 |
| Ocular neovascularization                | VEGF                  | Reich et al. 2003 |
| Alterations of synaptic function (retina) | APP/APLP2             | Herard et al. 2005 |
| Others                                   |                       |           |
| Induction of hypoglycemia and hypertriglyceridemia | PPARα | De Souza et al. 2006 |
| Attenuation of morbidity and mortality in sepsis | Fas, caspase-8 | Wesche-Soldato et al. 2005 |
| Collagen-induced arthritis               | TNFα                  | Schifflers et al. 2005 |
| Cure of collagen-induced arthritis       | TNFα                  | Khoury et al. 2006 |
| Role of V2R in water/sodium homeostasis  | V2R                   | Hassan et al. 2005 |
| Increased metabolic rate/decreased body weight | Agouti-related peptide | Makimura et al. 2002 |
| Inflammation (peritoneum)                | IL-12p40              | Flynn et al. 2004 |
| Sepsis after lipopolysaccharide injection | TNF-α                 | Sorensen et al. 2003 |
| Reduction of apoB and total cholesterol  | ApoB                  | Soutschek et al. 2004 |
| Abrogation of HSF-induced cardioprotection | Heat shock factor 1   | Yin et al. 2005 |
| Hearing loss                             | GJBR75W               | Maeda et al. 2005 |
Nanoparticles

Another strategy allowing the protection and cellular delivery of siRNAs is the formation of nanoparticles with positively charged macromolecules. Based on electrostatic interactions, complexes are formed with atelocollagen (Banno et al. 2006; Minakuchi et al. 2004; Takei et al. 2004; Takeshita et al. 2005), chitosan (Pille et al. 2006), or polyethylenimine (PEI).

Polyethylenimine

PEIs are synthetic linear or branched polymers available in a wide range of molecular weights (Godbey et al. 1999; Tang and Szoka 1997). Due to the presence of a protonable amino group in every third position, leading to a high cationic charge density at physiological pH, PEIs are able to form noncovalent complexes with DNA as well as small RNA molecules like siRNAs (Urban-Klein et al. 2005) or ribozymes (Aigner et al. 2002). This siRNA complexation results in the complete protection against degradation in the presence of serum or RNase A and allows the efficient cellular uptake of the PEI/siRNA complexes through endocytosis. For any siRNA formulation, the release from endosomes is critical for siRNA delivery. In the case of PEI, the so-called “proton-sponge effect” postulates improved transgene delivery by cationic complexes, which contain H+-buffering polyamines, based on enhanced endosomal Cl− accumulation and subsequent osmotic swelling and lysis (Behr 1997; Bousif et al. 1995). This effect may also apply for PEI-mediated siRNA delivery into the cytoplasm. Additionally, to further enhance the efficacy of PEI complexes through membrane destabilization, the conjugation of melittin analogs to PEI has been described (Boeckle et al. 2005, 2006; Shir et al. 2006). It should be noted, however, that by far not all PEIs are suitable for the transport of nucleic acids like siRNAs (Hassani et al. 2005; Werth et al. 2006).

---

**Table 2** In vivo application of siRNAs for the induction of RNAi: modes of administration of naked or formulated siRNAs

| Modes of administration                              | Example references                                                                 |
|-------------------------------------------------------|--------------------------------------------------------------------------------------|
| Hydrodynamic transfection                             | Bradley et al. 2005a, b; Duxbury et al. 2004; Giladi et al. 2003; Hamar et al. 2004; Hino et al. 2006; Klein et al. 2003; Lewis et al. 2002; Liang et al. 2005; Matsui et al. 2005; Merl et al. 2005; Sato et al. 2005; Song et al. 2003; Tompkins et al. 2004; Zender et al. 2003 |
| Intravenous (without high pressure)                   | Bradley et al. 2005a, b; Chien et al. 2005; Ge et al. 2004; Hassan et al. 2005; Miyawaki-Shimizu et al. 2005; Morrissy et al. 2005a, b; Schifferlers et al. 2004; Soutschek et al. 2004; Yano et al. 2004; Takeshita et al. 2005 |
| Intraperitoneal                                        | Filleur et al. 2003; Flynn et al. 2004; de Jonge et al. 2005; Ocker et al. 2005; Sorensen et al. 2003; Verma et al. 2003; Urban-Klein et al. 2005; Yin et al. 2005 |
| Intramuscular                                          | Golzio et al. 2005                                                                 |
| Intratracheal                                          | Lomas-Neira et al. 2005; Perl et al. 2005                                           |
| Intranasal                                             | Bitko et al. 2005; Zhang et al. 2004a, b                                           |
| Subretinal                                             | Reich et al. 2003                                                                   |
| Intraocular                                             | Herard et al. 2005                                                                  |
| Intradermal                                            | Kim et al. 2005                                                                     |
| Subcutaneous                                           | Yano et al. 2004                                                                    |
| Intrathecal                                            | Dorn et al. 2004; Luo et al. 2005                                                   |
| Stereotactic injection to hypothalamus                 | Makimura et al. 2002                                                                |
| Infusion into the ventricular system (brain)           | Hassani et al. 2005; Thakker et al. 2004, 2005                                        |
| Intrathecal infusion using mini-osmotic pump           | Dorn et al. 2004                                                                   |
| In situ perfusion/intravenous (pancreatic islet)       | Bradley et al. 2005a, b                                                             |
| Intracardiac                                           | Bollerot et al. 2006                                                                |
| Intratumoral                                           | Bertrand et al. 2002; Ito et al. 2005; Leng and Mixson 2005; Takei et al. 2004     |
| Intratumoral+electroporation                           | Takahashi et al. 2005                                                               |
| Renal artery and electroporation                       | Takabatake et al. 2005                                                             |
| Transurethral (bladder cancer)                         | Nogawa et al. 2005                                                                  |
| Local (ear, tracheal grafts, liver, optic nerve stump) | Fukuyama et al. 2005; Lingor et al. 2005; Maeda et al. 2005; McCaffrey et al. 2002 |
| Local injection and electroporation (mouse joint)      | Schifferlers et al. 2005                                                           |
In vivo studies in xenografted mice have demonstrated that the i.p. injection of PEI-complexed siRNAs, but not of naked siRNAs, resulted in the delivery of intact siRNA molecules into the subcutaneous tumors, leading to antitumorigenic effects when targeting for example the receptor HER-2 in s.c. ovarian carcinoma xenografts (Urban-Klein et al. 2005) or the growth factors pleiotrophin (PTN, s.c. glioblastoma) (Grzelinski et al. 2006) or VEGF (s.c. prostate carcinoma; Hobel et al., unpublished data). Likewise, intrathecal delivery of PEI-complexed specific siRNAs led to successful PTN targeting and tumor inhibition in an ortotopic glioblastoma mouse model (Grzelinski et al. 2006), or to the knockdown of the N-methyl-d-aspartate (NMDA) receptor subunit protein NR2B in a rat model (Tan et al. 2005). PEI complexation of siRNAs has also been employed in antiviral therapy studies (Ge et al. 2004; Geisbert et al. 2006). Furthermore, PEI/siRNA complexes are a good example for the introduction of chemical modifications to enhance tissue specificity and in vivo biocompatibility, to reduce immunogenicity and toxicity and to increase siRNA delivery through improved endocytosis and intracellular siRNA release. This includes full deacetylation of PEI (Thomas et al. 2005), the introduction of novel low molecular weight PEIs (Werth et al. 2006), and the coupling of PEI to other macromolecules like polyethylene glycol (PEG), either alone (Mao et al. 2006) or in combination with a ligand for tissue-specific targeting (RGD peptide for the recognition of tumor vasculature; Schiffelers et al. 2004).

### Chemical siRNA modifications

Alternatively, the goals of increased systemic siRNA stability and serum half-life have also been achieved...
through extensive chemical modifications of the siRNA strands including the introduction of phosphorothioate (Braasch et al. 2003, 2004), 4'-thioribose (Dande et al. 2006) or methylene linkages between positions 2' and 4' (locked nucleic acids, LNAs; Braasch et al. 2003; Elmen et al. 2005), or multiple 2' modifications (Amarzguioui et al. 2003; Harborth et al. 2003; Holen et al. 2002, 2003). Additionally, chemical conjugation of siRNAs, e.g., to cholesterol (Soucek et al. 2004) or to a protamine-antibody fusion protein (Song et al. 2005) led to enhanced efficacy and specificity in tissue uptake. For other strategies, refer to Table 3.

Conclusion and outlook

RNAi has already proven to be a very efficient and specific method for the knockdown of physiologically or pathologically relevant genes of interest. Notably, this also applies to so-called “nondruggable” genes, thus opening new therapeutic avenues. Still, the therapeutic applicability and success of siRNAs will largely depend on their efficient targeting and specificity through optimal siRNA sequences and an at least somewhat combination of a high target gene specificity through gene knockdown will be their forte for formulated, modified, or unmodified siRNAs for successful gene silencing. Most likely, one major advantage of formulated, modified, or unmodified siRNAs for gene knockdown will be their “double specificity”, i.e., the combination of a high target gene specificity through optimal siRNA sequences and an at least somewhat increased target organ specificity through sophisticated delivery vehicles like liganded nanocarriers.

Acknowledgments

The author’s work reported herein was supported by grants from the Deutsche Forschungsgemeinschaft (Ai 24/5-1 and Forschergruppe Nanohale, Ai 24/6-1) and by the Deutsche Krebshilfe.

References

Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F (2002) Delivery of unmodified active ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 9:1700–1707
Amarzguioui M, Holen T, Babaie E, Prydz H (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31:589–595
Amarzguioui M, Peng Q, Wiiger MT, Vasovic V, Babaie E, Holen T, Nesland JM, Prydz H (2006) Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 12:4055–4061
Banno H, Takei Y, Muramatsu T, Komori K, Kadomatsu K (2006) Controlled release of small interfering RNA targeting midkine attenuates intimal hyperplasia in vein grafts. J Vasc Surg 44:633–641
Behlke MA (2006) Progress towards in vivo use of siRNAs. Mol Ther 13:644–670
Behr JP (1997) The proton sponge: a trick to enter cells the viruses did not exploit. Chimia 51:34–36
Bernstein E, Caudy AA, Hammond SM, Hannon GJ (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409:363–366
Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malcy V (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 296:1000–1004
Bitko V, Musiyenko A, Shulyayeva O, Barik S (2005) Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 11:50–55
Boeckele S, Wagner E, Ogris M (2005) C- versus N-terminally linked melitin-polyethylenimine conjugates: the site of linkage strongly influences activity of DNA polyplexes. J Gene Med 7:1335–1347
Boeckele S, Fahrmeir J, Roedl W, Ogris M, Wagner E (2006) Melittin analogs with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J Control Release 112:240–248
Bollerot K, Sugiyama D, Escriou V, Gautier R, Tozer S, Scherman D, Jaffredo T (2006) Widespread lipoplex-mediated gene transfer to vascular endothelial cells and hemangioblasts in the vertebrate embryo. Dev Dyn 235:105–114
Boussif O, Lezoualc’h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92:7297–7301
Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42:7967–7975
Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP, Corey DR (2004) Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 14:1139–1143
Bradley SP, Kowalik TF, Rastelli C, da Costa MA, Bloomenthal AB, Cicales L, Basadonna GP, Uknis ME (2005a) Successful incorporation of short-interfering RNA into islet cells by in situ perfusion. Transplant Proc 37:233–236
Bradley SP, Rastelli C, da Costa MA, Kowalik TF, Bloomenthal AB, Brown M, Cicales L, Basadonna GP, Uknis ME (2005b) Gene silencing in the endocrine pancreas mediated by short-interfering RNA. Pancreas 31:373–379
Bridge AJ, Pebernard S, Ducruix A, Nicoulaz AL, Iggo R (2003) Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 34:263–264
Chien PY, Wang J, Carbonaro D, Lei S, Miller B, Sheikh S, Ali SM, Ahmad MU, Ahmad I (2005) Novel cationic cardiolipin analogues with high lytic activity at endosomal pH enhance transfection with purified targeted PEI polyplexes. J Control Release 112:240–248
Collins RE, Cheng X (2005) Structural domains in RNAi. FEBS Lett 579:5841–5849
Dande P, Prakash TP, Sioufi N, Gaus H, Jarres R, Berdeja A, Swayze EE, Griffey RH, Bhat B (2006) Improving RNA interference in mammalian cells. Nat Genet 34:263–264
de Jonge J, Holtrop M, Wilschut J, Huckriede A (2006) Reconstituted influenza virus envelopes as an efficient carrier system for cellular delivery of small-interfering RNAs. Gene Ther 13:400–411
De Souza AT, Dai X, Spencer AG, Reppen T, Menzie A, Roesch PL, He Y, Caguyong MJ, Bloomer S, Herweijer H et al (2006) Aigner A, Fischer D, Merdan T, Brus C, Kissel T, Czubayko F (2002) Delivery of unmodified active ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther 9:1700–1707
Amarzguioui M, Holen T, Babaie E, Prydz H (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 31:589–595
Amarzguioui M, Peng Q, Wiiger MT, Vasovic V, Babaie E, Holen T, Nesland JM, Prydz H (2006) Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 12:4055–4061
Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockout mice. Nucleic Acids Res 34:4486–4494

Dorn G, Patel S, Woutersen G, Hemmings-Miesczak M, Barclay J, Natt FJ, Martin P, Bevan S, Fox A, Ganju P et al (2004) siRNA relieves chronic neuropathic pain. Nucleic Acids Res 32:e49

Duxbury MS, Matros E, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) Systemic siRNA-mediated gene silencing: a new approach to targeted therapy of cancer. Ann Surg 240:667–674 (discussion 675–666)

Dykxhoorn DM, Lieberman J (2006) Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu Rev Biomed Eng 8:377–402

Elbashir SM, Lendeckel W, Tuschl T (2001a) RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15:188–200

Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber T, Kusel T (2001b) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498

Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T et al (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33:439–447

Filleur S, Courtin A, Ait-Si-Ali S, Guglielm J, Merle C, Harel-Bellan A, Clezardin P, Cabon F (2003) SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 63:3919–3922

Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811

Flynn MA, Casey DG, Todryk SM, Mahon BP (2004) Efficient delivery of small interfering RNA for inhibition of IL-12p40 expression in vivo. J Inflam 1:1–4

Fujii T, Sakurai M, Iwasaki E, Iwasaki N, Nakamura M, Kubushiro K et al (2006) Intratumor injection of small interfering RNA targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int J Oncol 29:541–548

Fukuyama S, Yoshino I, Yamaguchi M, Osogawa A, Kameyama Y, Tagawa T, Maehara Y (2005) Blockage of the macrophage migration inhibitory factor expression by short interference RNA inhibited the rejection of an allogeneic tracheal graft. Transpl Int 18:1203–1209

Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J (2004) Inhibition of influenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA 101:8676–8681

Geisbert TW, Hensley LE, Kagan E, Yu EZ, Geisbert JB, Daddario-Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (2006) Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs. Annu Rev Biomed Eng 8:377–402

Hassan A, Tian Y, Zheng W, Ji H, Sandberg K, Verbalis JG (2005) Small interfering RNA-mediated functional silencing of vasopressin V2 receptors in the mouse kidney. Physiol Genomics 21:382–388

Hassans Z, Lemkine GF, Erbacher P, Palmeri K, Alfama G, Giovannangeli C, Behr JP, Demeneix BA (2005) Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levels. J Gene Med 7:198–207

Heidel JD, Hu S, Liu X, Triche J, Davis ME (2004) Lack of interferon response in animals to naked siRNAs. Nat Biotechnol 22:1579–1582

Heil F, Hemmi H, Hochrein H, Ambenenser F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526–1529

Herard AS, Besret L, Dubois A, Dauguet J, Delzescaux T, Hantraye P, Bonventro G, Moya KL (2006) siRNA targeted against amyloid precursor protein impairs synaptic activity in vivo. Neurobiol Aging 27:1740–1750

Hino T, Yokota T, Ito S, Nishina K, Kang YS, Mori S, Horii S, Kanda T, Terasaki T, Mizusawa H (2006) In vivo delivery of small interfering RNA targeting brain capillary endothelial cells. Biochem Biophys Res Commun 340:263–267

Hogretege A, Lebedev AV, Zot G, Pirrollo KF, Rait A, Zhou Q, Yu W, Chang EH (2006) Chemically modified short interfering hybrids (siHYBRIDS): nonimmunomolosipose delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25:889–907

Holen T, Amargiuoi M, Wiiger MT, Babaie E, Prydz H (2002) Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res 30:1757–1766

Holen T, Amargiuoi M, Babaie E, Prydz H (2003) Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common RNAi pathway. Nucleic Acids Res 31:2401–2407

Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, et al (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263–270

Hou JQ, He J, Wang XL, Wen DG, Chen XZ (2006) Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer. Chin Med J (Engl) 119:1734–1739

Howard KA, Rahbek UL, Liu X, Damgaard CK, Glud SZ, Andersen MO, Hovgaard MB, Schmitz A, Nyengaard JR, Besenbacher F et al (2006) RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 14:476–484
Ito M, Yamamoto S, Nimura K, Hiraoka K, Tamai K, Kaneda Y (2005) Radi51 siRNA delivered by HVJ envelope vector enhances the anticancer effect of cisplatin. J Gene Med 7:1044–1052

Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS (2003) Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 21:635–637

Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23:457–462

Khoury M, Louis-Pence P, Escricou V, Noel D, Largeau C, Cantos C, Scherman D, Jorgensen C. Apparally F (2006) Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum 54:1867–1877

Kim TW, Lee JH, He L, Boyd DA, Hardwick JM, Hung CF, Wu TC (2005) Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. Cancer Res 65:309–316

Klein C, Bock CT, Wedemeyer H, Wustefeld T, Locarnini S, Dienes HP, Kubicka S, Manns MP, Trautwein C (2003) Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. Gastroenterology 125:9–18

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Beresteen G, Sood AK (2005) Therapeutic Epha2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910–6918

Liu J, Carmell MA, Williams L, Chang C and others (2005) Silencing of fas, but not caspase-8, in lung xenograft model of human prostate cancer. Int J Oncol 26:1087–1091

Mao S, Neu M, Gersmehaus O, Sitterberg J, Bakowsky U, Michel HP, Kubicka S, Li H, Blot E, Bertrand J, Opolon P, Maksimenko A, Lu H, Vannier JP, Soria J et al (2006) Intravenous delivery of antiRhoA small interfering RNA loaded in nano-
particles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum Gene Ther 17:1019–1026

Pirrollo KF, Zon G, Rait A, Zhou Q, Yu W, Hogrefe R, Chang EH (2006) Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum Gene Ther 17:117–124

Rand TA, Ginalska K, Grishin NV, Wang X (2004) Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc Natl Acad Sci USA 101:14385–14389

Reich SJ, Fosnot J, Kuroki A, Tang W, Yang X, Maguire AM, Bennett J, Tolentino MJ (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol Vis 9:210–216

Rivas FV, Tolia NH, Song JJ, Aragon JP, Liu J, Hannon GJ, Joshua-Tor L (2005) Purified Argonaute2 and an siRNA form recombiant human RISC. Nat Struct Mol Biol 12:340–349

Santel A, Alekou M, Keil O, Endruchst J, Esche V, Fisch G, Dames S, Loffler K, Fechtmier M, Arnold W et al (2006a) A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Therapy 13:1222–1234

Santel A, Alekou M, Keil O, Endruchst J, Esche V, Durieux B, Loffler K, Fechtmier M, Rohl T, Fisch G et al (2006b) RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther 13:1360–1370

Sato Y, Ajiki T, Inoue S, Fujishiro J, Yoshino H, Igarashi Y, Hakamata Y, Kaneko T, Murakamid T, Kobayashi E (2005) Gene silencing in rat-liver and limb grafts by rapid injection of small interference RNA. Transplantation 79:240–243

Schiffelers RM, Ansari A, Xu J, Zhou Q, Tang Q, Storm G, Molema G, Lu PY, Scaria PV, Woodle MC (2004) Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 32:e149

Schiffelers RM, Xu J, Storm G, Woodle MC, Scaria PV (2005) Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum 52:1314–1318

Shen J, Samul R, Silva RL, Akiyama H, Liu H, Saishin Y, Hackett SF, Schiffelers RM, Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB (2003) Small interfering RNAs directed against the beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9:1291–1300

Urban-Klein B, Merth S, Abuharbeid S, Czubayko F, Aigner A (2005) RNAi-mediated gene-targeting through systemic application of polyethyleneimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461–466.

Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB (2003) Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 9:1291–1300

Wesche-Soldato DE, Chung CS, Lomas-Neim J, Doughty LA, Gregory SH, Ayala A (2005) In vivo delivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 106:2295–2301

Yano J, Hirabayashi K, Nakagawa S, Yamaguchi T, Nagawa M, Kashimori I, Naito H, Kitagawa H, Ishiyama K, Ohgi T et al (2004) Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 10:7721–7726
Yin C, Xi L, Wang X, Eapen M, Kukreja RC (2005) Silencing heat shock factor 1 by small interfering RNA abrogates heat shock-induced cardioprotection against ischemia-reperfusion injury in mice. J Mol Cell Cardiol 39:681–689
Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gosling T, Flemming P, Malek NP et al (2003) Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci USA 100:7797–7802
Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, Dean DA, Liu D (2004a) Hydroporation as the mechanism of hydrodynamic delivery. Gene Ther 11:675–682
Zhang X, Shan P, Jiang D, Noble PW, Abraham NG, Kappas A, Lee PJ (2004b) Small interfering RNA targeting heme oxygenase-1 enhances ischemia-reperfusion-induced lung apoptosis. J Biol Chem 279:10677–10684
Zhu H, Liang ZY, Ren XY, Liu TH (2006) Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo. Cancer Biol Ther 5:1693–1698
Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M et al (2006) RNAi-mediated gene silencing in nonhuman primates. Nature 441:111–114